POLB announces today that it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. Importantly POLB was safe and well tolerated and the team will be able to use this dataset as part of their discussions with potential partners at the annual JPMorgan Conference in January 2023. The full read out of ....

12 Dec 2022
Successful completion of POLB 001 LPS challenge trial

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful completion of POLB 001 LPS challenge trial
Poolbeg Pharma PLC (POLB:LON) | 7.2 0 3.6% | Mkt Cap: 36.2m
- Published:
12 Dec 2022 -
Author:
Karl Keegan -
Pages:
3 -
POLB announces today that it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. Importantly POLB was safe and well tolerated and the team will be able to use this dataset as part of their discussions with potential partners at the annual JPMorgan Conference in January 2023. The full read out of ....